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Possible role of tumor necrosis factor and interleukin-l in the develop-
ment of diabetic nephropathy. The possibility that tumor necrosis factor
(TNF) and interleukin-l (IL-i) could participate in the development of
diabetic nephropathy was evaluated in streptozocin (STZ)-treated dia-
betic rats. Diabetic rats were divided into two groups: aminoguanidine
treated group (25 mg/kg body wt, daily i.p. injection; DM-AG group)
and untreated group (DM group). Non-diabetic age-matched rats were
also divided into two groups with the same manner and used as
controls. After twelve weeks of treatment, glomerular basement mem-
branes (GBM) were isolated from rats of each experimental group.
When thioglycollate-elicited peritoneal macrophages (M4) from normal
rats were incubated with these GBM materials, GBM from DM group
induced significantly greater levels of TNF and IL-I production than did
GBM from other three groups with at doses of 2.5 to 10 mg. The TNF
and IL-I production by stimulation of GBM from the DM-AG group
were similar to those from each control group. Aminoguanidine treat-
ment significantly decreased the accumulation of advanced glycation
end-products (AGEs) in GBM of diabetic rats. These findings suggest
that AGE-proteins may be involved in the production of TNF and IL-i
from Mq. AGE-induced cytokines may be implicated in the develop-
ment of diabetic nephropathy.
Two major monocyte-macrophage derived cytokines, tumor
necrosis factor (TNF) and interleukih 1 (IL-i), have broad
biological activities on various target cells. Recently, a possible
role of these cytokines in the pathogenesis of various disorders
has been suggested [1, 2]. However, there have been no reports
so far that associated diabetic nephropathy with these cyto-
kines.
Non-enzymatic glycation of proteins, with subsequent forma-
tion of advanced glycation end-products (AGEs), is thought to
play an important role in the development of diabetic compli-
cations [3, 41. AGEs accumulate on long lived structural pro-
teins such as collagen under diabetic hyperglycemia, through a
complex series of chemical rearrangements of the nonenzy-
matic addition product of glucose with free amino groups, the
Amadori product [5, 6]. It has been suggested that an acceler-
ated formation of AGEs in diabetic patients could cause the
structural and functional alterations in tissues involved in
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microvascular and macrovascular diabetic complications. Fur-
thermore, binding of AGE-modified proteins to macrophages
(M4i) was recently found to stimulate synthesis and release of
TNF and IL-i [7]. Other previous studies [8, 9] have docu-
mented an increase of glycation and AGE accumulation in
glomerular basement membrane of streptozocin (STZ)-treated
diabetic animals. These findings awake interest in the possibil-
ity that cytokines participate in the pathogenesis of diabetic
nephropathy.
In this study, we evaluated the possibility that TNF and IL-i
could participate in the development of diabetic nephropathy,
using streptozocin (STZ)-treated diabetic rats.
Methods
Animals
Male Lewis rats aged seven to eight weeks (Charles River
Japan, Tokyo, Japan) were rendered diabetic by i.v. injection of
STZ (60 mg/kg; Upjohn, Kalamazoo, Michigan, USA) dis-
solved in citrate buffer (pH 4.5). One week after injection, the
animals with a blood glucose level above 350 mg/dl were
selected for the present study. Then, these diabetic rats were
divided into two groups of same blood glucose levels. One
received daily i.p. injection of sterile saline alone (DM group).
The another group was injected with sterile saline containing
aminoguanidine (25 mg/kg body wt, Tokyo Kasei Kogyo Co.,
Tokyo, Japan), which has been reported to inhibit AGE forma-
tion and glucose-derived collagen cross linking in vivo (DM-AG
group) [10]. Non-diabetic age-matched rats undergoing similar
treatments were used as controls (C group and C-AG group).
Measurement of blood glucose levels and glycated
hemoglobin (HbA1)
Fed blood glucose levels (0900 to 1100 hr) were monitored
every two weeks in whole blood obtained by tail snipping and
measured by the glucose oxidase method (DRI-CHEM 2000;
Fuji Medical System Co., Tokyo, Japan). HbAI was measuied
every four weeks by affinity chromatography using a commer-
cially available kit (Glycohemoglobin-test Wako, Wako Phar-
maceutical Co., Osaka, Japan).
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when compared with the GBM materials used in previous
studies [13, 14].
Preparation of M4
Thioglycollate (TG)-elicited peritoneal M4 were obtained
according to the method of Kumagai et al [15] from normal
Lewis rats (aged 7 to 8 weeks) injected i.p. with 5 ml of 3% TG
broth (Difco, Detroit, Michigan, USA) four days before har-
vest. The purity of M4 by this procedure was more than 95%,
which was confirmed by cytochemical elastase staining.
Incubation of M4 with GBM
Fig. 1. Light micrograph of the GBM material. GBM was fixed in cold
2% glutaraldehyde buffered in sodium cacodylate pH 7.4, embedded in
vestpol. One jm sections were stained with Toluidine blue. GBM
appears as loops or plates with no cells attached. x500.
Measurement of urinary albumin
Twenty-four-hour urine collections were obtained every four
weeks for the measurement of urinary albumin content. Urinary
albumin levels were measured by radioimmunoassay, using
rabbit anti-rat albumin (Cappel, West Chester, Pennsylvania,
USA) as a first antibody and sheep anti-rabbit IgG (Pharmacia,
Uppsala, Sweden) as a second antibody.
Isolation of glomerular basement membranes (GBM)
GBM were isolated according to Cohen and Carlson [11] with
minor modification. After twelve weeks of the treatment, rats
from each of the four groups were lightly anesthetized with
ether and killed by decapitation. The kidneys were rapidly
removed from each rat and placed on ice. The decapsulated
cortices were separated, and pooled for each group of four to
five rats. Glomeruli were isolated by serial sieving and retained
on 63 sm nylon screens. Tubular contamination was consis-
tently less than 5%. The glomeruli were suspended in 20 ml of
ice-cold 1 M sodium chloride, buffered with 25 mrvi Tris to pH
7.2, and containing protease inhibitors. They were sonicated in
an ice bath using ASTRASON W-380 (Heat System-Ultrason-
ics, Farmingdale, New York, USA). The sonicator was set at
power output "9", cycle rate '5", % duty cycle "50", and
used a one minute burst with a one minute cooling time. After
total sonicatjon time of 12 minutes, the sonicated materials
were passed over a 63 Lm nylon screen. The basement mem-
branes was settled by centrifugation at 800 g for 15 minutes at
4°C. GBM fractions were washed several times with 1 M NaCI
containing protease inhibitors, followed by distilled water
alone. Then, the GBM fractions were weighed and suspended in
RPMI medium at a known concentration.
In this procedure, the mean phosphorous content, an indica-
tor of the purity of the preparation, was 0.58 0.052 jsg/mg of
dry weight GBM (mean SEM, N = 12), which was measured
according to Bartlett [12]. Furthermore, light microscopy indi-
cated that these GBM preparations were free of cells or
recognizable cell fragments with a little amount of debris (Fig.
I). These results indicate that this preparation is equally pure
M4 (1 x 106 cells) were resuspended in 1.5 ml of RPMI
supplemented with streptomycin (100 p.g/ml), penicillin (100
U/mi), and 5% FCS in 24-well tissue culture plates. Time-
course of GBM-induced TNF and IL-l production by M was
evaluated by adding 10 mg (wet weight) of GBM from DM or C
group to each well. The samples were collected after 2 to 48
hours of incubation at 37°C in a humidified 5% CO2 atmosphere.
As shown in Figure 4, major peaks of IL-l and TNF activities
were at 24 hours. Therefore, 24 hours of incubation was applied
to the comparison among DM, DM-AG, C, and C-AG group.
Then, 1.25, 2.5, 5 or 10 mg GBM (wet weight) from each group
of rats were added to each well. Control wells contained either
M4 or 10 mg of GBM alone. After incubation for 24 hours, the
supernatants were harvested and stored —20°C before assay for
TNF and IL-i. All reagents contained less than 0.050 ng of
endotoxinlml as quantified by the limulus amebocyte lysate
assay (LIMUTESTER; Funakoshi, Tokyo, Japan).
TNF and IL-i assay
TNF levels were assayed by monitoring the lysis of LM cells
in the presence of actinomycin D, using human TNFs (Dainip-
pon Pharmaceutical Co., Osaka, Japan) as the standard [161.
IL-I levels were assayed by the enhancement of C3H/Hej
mouse thymocyte proliferation in response to PHA (Difco),
using human IL-la (Dainippon Pharmaceutical Co.) as the
standard [17]. The specificities of assays of TNF and IL-l were
studied in the selected samples by blocking experiments with
rabbit anti-mouse TNFa (provided by Suntory Laboratory
Center, Osaka, Japan) or rabbit anti-mouse IL-la (kindly
provided from Dr. Katsuji Nakano, Dainippon Pharmaceutical
Co., Osaka, Japan). Equal volumes of test samples were mixed
with asiti-mouse TNFa serum (at a dilution of 1:100) or anti-
mouse IL-i a serum (at a dilution of 1:200). After incubation at
37°C in 5% CO2 for 30 minutes, residual TNF or IL-I activity
was determined. Furthermore, to determine whether de novo
protein synthesis was required for GBM-induced TNF and IL-I
secretion of M, cells were treated with cycloheximide (0.2
g/ml) for 24 hours in the presence of GBM. This condition did
not affect the viability of cells as determined by Trypan blue
exclusirjn
ifrasurement of AGE and nonenzymatic glycation
In a separate experiment, GBM samples were obtained from
each group of rats after 12 weeks of aminoguanidine or saline
treatment as described above. We used four to five rats per
group for the preparation of GBM samples and made five sets of
GBM samples in order to derive the mean values. Freeze dried
GBM samples were solubilized by incubation for 72 hours at
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37°C with highly purified collagenase (Advance, Linbrook, New
York, USA) (1000 U/mg GBM in 0.5 M phosphate buffer
containing 1 m sodium azide, pH 7.4). The solubilized GBM
fraction was analyzed by measuring the fluorescence at 440 nm
upon excitation at 370 nm, using a Hitachi 650-40 model
fluorometer (Hitachi, Tokyo, Japan) [181. An aliquot of solubi-
lized sample was hydrolyzed with 6 N HC1 for 22 hours at
110°C. Then, it was placed on an amino acid analyzer (Shi-
madzu LC-6A Amino Acids Analysis System, Shirnadzu, Ky-
oto, Japan) for determination of hydroxyproline levels. The
results were expressed as fluorescent intensity/p.mol hydroxy-
proline. Portions of the GBM samples were solubilized with 1 N
NaOH and nonenzymatic glycation of protein was estimated by
a thiobarbituric color assay [191. Protein was measured by the
method of Lowry et al [201.
Statistics
Data are presented as mean SEM. Statistical analysis was
performed by analysis of variance with significance at P < 0.05.
Further specific group differences were determined by Dun-
can's multiple range test.
Fed blood glucose and HbAJ levels
Fed blood glucose levels in DM and DM-AG groups at the
beginning of the treatment were 451.9 14.5 and 455.3 11.4
mg/dl, respectively, (Fig. 2). Thereafter, high blood glucose
levels were maintained in these two groups, and aminoguani-
dine treatment did not affect the blood glucose levels in either
diabetic or normal rats. Similarly, DM and DM-AG groups
maintained high HbA1 levels throughout the study, and there
were no significant differences between the two groups.
Urinary albumin excretion
Diabetic rats already had values significantly elevated (P <
0.05) over the normal rats at one week after the injection of STZ
(Fig. 3). The excretion rates in DM and DM-AG groups
progressively increased until 12 weeks of the study. DM-AG
group had slightly lower value than DM group at 12 weeks,
however, there were no significant differences.
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Fig. 2. Fed blood glucose and HbA1 profiles in
the four experimental groups. HbA1 levels in DM
and DM-AG rats were significantly elevated (P <
0.01) than those in two control groups. Data are
0 2 4 6 8 10 12 shown as means SEM. Symbols are: (•—) DM(N = 15); (0---) DM-AG (N = 15); (A—) C (N =
Time, weeks of treatment 15); (L---) C-AG (N = 15).
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Fig. 3. Urinary albumin excretion profiles in the four experimental
groups. The urinary albumin excretion in DM and DM-AG rats were
significantly elevated at all points. Aminoguanidine treatment did not
significantly suppress diabetes induced albuminuria. Data are shown as
means SEM. Symbols are (•—) DM (N 15); (0---) DM-AG (N =
15); (A—) C (N = 15); (---) C-AG (N = 15). *D <0.05, ** P <0.01 vs.
C and C-AG group.
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Fig. 4. Time course curves of TNF and IL-i production from TG-
elicited Mb induced by GBM from DM and C group. M were
incubated in the presence of 10 mg of GBM from each group and the
supernatants were collected at the times indicated. Data are shown as
means SEM of four experiments, with triplicate determination.
Symbols are: DM (S—); C (0—); Mçb alone (z—).
TNF and IL-I production by M4 in response to GBM
The time course for the production of TNF and IL-i from M4
in response to diabetic or normal GBM is shown in Figure 4. A
slight TNF activity was detectable after four hours of incuba-
tion in the presence of 10 mg of diabetic GBM. The levels
increased for up to 24 hours. IL-I activity was also detectable
after four hours of incubation. A major peak of activity was
detected at 24 hours, and the rising of the kinetic curve during
first eight hours was steeper than that of TNF activity. Identical
results were obtained in the presence of normal GBM, although
the levels were low and a longer period was needed to detect the
activity.
The GBM-induced TNF activity was completely blocked by
rabbit anti-mouse TNFa. The IL-i activity was also completely
neutralized by rabbit anti-mouse IL-i a. Activities of both
cytokines became undetectable by treating the M4 with cyclo-
heximide, indicating that de novo protein synthesis was re-
quired.
TNF and IL-i productions from M4 after 24 hours' incuba-
tion with GBM from the DM, DM-AG, C, and C-AG groups are
shown in Figure 5. GBM from DM rats induced significantly
greater levels of TNF and IL-l production from M4 than did
GBM from other three groups at doses of 2.5 to 10 mg.
Dose-dependent productions of both cytokines were also ob-
served. On the other hand, TNF and IL-i productions from M4
induced by GBM from DM-AG rats were similar to those
induced by GBM from C and C-AG rats. No activities of either
cytokine was detected when GBM, regardless of diabetic or
normal, was incubated alone.
Nonenzymatic glycation and AGE accumulation in GBM
Nonenzymatic glycation of proteins developed in GBM from
DM rats (Table 1). Treatment with aminoguanidine did not
modify the level of nonenzymatic glycated proteins. Further-
more, the accumulation of fluorescent AGEs in GBM from DM
rats was significantly greater than those in GBM from other
three groups (P < 0.01). In aminoguanidine-treated diabetic
animals exposed to identical levels of hyperglycemia, however,
the level was nearly normal.
Discussion
Glomerulus consists of cellular and matrix (GBM and mesan-
gial matrix) component. In the isolation procedure for GBM,
regardless of sonic disruption or osmotic lysis-detergent treat-
ment, the contamination with mesangial matrix cannot be
excluded. We showed that these GBM materials from diabetic
rats stimulated M4 to produce greater levels of TNF and IL-i
than did normal GBM. In the preliminary study, there were no
differences in TNF and IL-i production in response to diabetic
GBM between M4 of diabetic rats (13 weeks after STZ injec-
tion) and those of normal rats (data not shown).
Aminoguanidine is thought to bind to glycated proteins, thus
preventing further progression to AGEs [10]. It has been
reported that this agent prevents accumulation of AGEs in
aortic collagen or GBM in chemically-induced diabetic animals
[9, 10]. Our studies also demonstrated that aminoguanidine
treatment prevented the accumulation of AGEs in GBM of the
diabetic rats. Furthermore, these GBM materials did not stim-
ulate M4 to produce TNF and IL-i. Therefore, AGE-proteins,
which were accumulated on collagen or other structural pro-
teins of diabetic GBM, could stimulate M4 to produce TNF and
IL-i [7]. Brownlee et al [21, 22] reported that IgG was cova-
lently attached to AGE-collagen or AGE-GBM in proportion to
AGE concentration. In addition, this binding IgG retained the
ability to form immune complexes in situ. Their results suggest
the possibility that, other than AGEs, immune complexes could
become one of stimulatory factors for M4 [23].
GBM from normal and aminoguanidine-treated normal rats
also stimulated M4 to produce TNF and IL-i, although the
levels were low. Deposition of plasma proteins, such as IgG or
complement, in the kidneys of normal rats with an older age has
been indicated [24]. Unknown factors which were deposited or
trapped in GBM from plasma might stimulate M4 to release the
cytokines. Vissers et a! [23] found no productions of TNF and
IL- 1 by monocytes from peripheral blood upon stimulation by
normal GBM. The difference between the two sets of data may
result from the functional characteristics of effector cells used
in each experiment, that is, we used nonspecifically-induced
peritoneal exudate macrophages, to which Adams et al [25]
referred as responsive macrophages.
The glomerular mesangium has been shown to contain bone
marrow derived M4 [26], and a recent study has shown that
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Fig. 5. TNF and IL-I production by TG-elicited
peritoneal macrophages in response to GBM from
DM (solid bar), DM-AG (hatched bar), C (open bar),
and C-AG (stippled bar) groups. Cells are incubated
with GBM as detailed in the text. Diabetic GBM
induced significantly greater levels of TNF and IL-l
production than GBM of the other three groups.
Data are shown as means SEM of six experiments,
with a triplicate determination. *P < 0.01 vs. GBM
from the other three groups. N.D.; not detected.
Table 1. Contents of AGE and non-enzymatic glycated proteins in
GBM of the four experimental groups.
Groups N AGE contenta
Non-enzymatic
glycationb
DM
DM-AG
C
C-AG
5 3.43 0.36"
5 1.92 0.17
5 1.68 0.16
5 1.70 0.22
19.2
18.4 20d
9.2 0.5
8.9 0.9
Data are presented as means SEM.
a Specific fluorescence per smol hydroxyprolineb nmoles 5-hydroxymethylfurfuralaldehyde per mg protein
P < 0.01 vs. DM-AG, C, and C-AG groupsd P < 0.01 vs. C and C-AG group
cultured mesangial cells produce TNF and IL-i [27, 281. These
findings suggest that glomerular mesangial cells can act as
effector cells.
TNF and IL-l, produced by M in response to AGE-
proteins, are considered to account for the normal tissue
remodeling with the removal and replacement of extracellular
matrix components [7]. In the diabetic state, it has been
proposed that this normal tissue homeostasis may be disturbed
by increased AGE-protein cross linkings, which reduce the
susceptibility to digestion by nonspecific proteases, leading the
synthetic and proliferative responses to be enhanced [4]. The
contribution of TNF and IL-I to the pathogenesis of diabetic
nephropathy is suggested by the following observations: a) IL-i
can stimulate total protein and collagen synthesis by mesangial
cells, which would lead to expansion of the mesangium and
thickening of the GBM [29]. b) IL-I and TNF stimulate pros-
taglandin production by mesangial cells, which may be respon-
sible for the alteration of glomerular microcirculation [30]. c)
These cytokines induce endotheiial procoagulant activity and
also increase endothelial permeability [1, 31].
In a similar comparative study [23], GBM containing immune
complexes induced monocytes to secrete maximum levels of
TNF and IL-i. However, in the present study, TNF and IL-i
activities induced by diabetic GBM were low levels and they
were only two- to threefold increased in comparison with the
levels induced by normal GBM. This difference may be re-
flected in the pathological features of immune-mediated glomer-
ulonephritis and diabetic nephropathy, that is, in diabetic
nephropathy severe proliferative lesions, such as crescent
formation, are not seen. These findings would suggest that
cytokines are not a pathogenetic determinant of diabetic
nephropathy. The mechanism by which diabetic nephropathy
occurs is most likely multifactorial based on the chronic meta-
bolic disturbance. In combination with these factors, locally
released TNF and IL- 1 could act to accelerate the progression
of nephropathy.
Aminoguanidine treatment could not significantly suppress
the increase of urinary albumin excretion in the early stages of
STZ-treated diabetic rats, although the value after 12 weeks of
treatment was slightly lowered. This result suggests that hemo-
dynamic factors may be predominant for the increase of urinary
albumin excretion in these stages of experimental diabetes [32,
33]. The longer periods of study would be needed for the
evaluation of effect of aminoguanidine on nephropathy, because
AGEs are accumulated in tissue in time-dependent manner [5,
6].
In conclusion, our data indicate that TNF and IL-i may
participate in the development of diabetic nephropathy. AGE-
proteins, which were accumulated on diabetic GBM, may
stimulate effector cells to produce these cytokines. Further
analysis of the effects of cytokines would increase our under-
standing of the pathogenesis of diabetic nephropathy.
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